These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21911300)

  • 21. Biosimilar insulins.
    Heinemann L
    Expert Opin Biol Ther; 2012 Aug; 12(8):1009-16. PubMed ID: 22583127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The challenges of immunogenicity in developing biosimilar products.
    Wadhwa M; Thorpe R
    IDrugs; 2009 Jul; 12(7):440-4. PubMed ID: 19579165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective pharmaceutical regulation needs alignment with doctors.
    Ebbers HC; Pieters T; Leufkens HG; Schellekens H
    Drug Discov Today; 2012 Feb; 17(3-4):100-3. PubMed ID: 22001600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What are biosimilars and are they important?
    Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Indian manufacturer's perspective for harmonization of guidelines for similar biotherapeutic products.
    Babu PV
    Biologicals; 2011 Sep; 39(5):300-3. PubMed ID: 21816621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Registration of similar biological products--Singapore's approach.
    Poh J; Tam KT
    Biologicals; 2011 Sep; 39(5):343-5. PubMed ID: 21783381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The first subsequent entry biologic authorized for market in Canada: the story of Omnitrope, a recombinant human growth hormone.
    Klein AV
    Biologicals; 2011 Sep; 39(5):278-81. PubMed ID: 21783382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statistical considerations for confirmatory clinical trials for similar biotherapeutic products.
    Njue C
    Biologicals; 2011 Sep; 39(5):266-9. PubMed ID: 21807534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New clinical trials policy at FDA.
    Vastag B
    Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
    [No Abstract]   [Full Text] [Related]  

  • 31. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
    Cai XY; Gouty D; Baughman S; Ramakrishnan M; Cullen C
    Bioanalysis; 2011 Mar; 3(5):535-40. PubMed ID: 21388266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
    Milton MN; Horvath CJ
    Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
    [No Abstract]   [Full Text] [Related]  

  • 33. Biosimilar regulation in the EU.
    Kurki P; Ekman N
    Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-clinical safety studies on biosimilar recombinant human erythropoietin.
    Parnham MJ; Schindler-Horvat J; Kozlović M
    Basic Clin Pharmacol Toxicol; 2007 Feb; 100(2):73-83. PubMed ID: 17244255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of similar biotherapeutic products: scientific and regulatory challenges.
    Griffiths E; Thorpe R; Wadhwa M; Sohn Y
    Biologicals; 2011 Sep; 39(5):249. PubMed ID: 21925898
    [No Abstract]   [Full Text] [Related]  

  • 36. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of specifications for biotechnology products--perspective from Europe.
    Trouvin JH
    Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679
    [No Abstract]   [Full Text] [Related]  

  • 38. Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation.
    Malhotra H
    Biologicals; 2011 Sep; 39(5):321-4. PubMed ID: 21784652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilars--global issues, national solutions.
    Knezevic I; Griffiths E
    Biologicals; 2011 Sep; 39(5):252-5. PubMed ID: 21924623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intended use of reference products & WHO International Standards/Reference Reagents in the development of similar biological products (biosimilars).
    Thorpe R; Wadhwa M
    Biologicals; 2011 Sep; 39(5):262-5. PubMed ID: 21880508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.